| Budget Amount *help |
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 1989: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1988: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1987: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Research Abstract |
In this research project, we studied the frequency-dependent attenuation in the normal liver, spleen,thyroid gland, breast tissue,muscle and brain.
On the other hand, some diseases of liver, thyroid gland , breast were studied using the spectral-shift zero-crossing method.
1; Frequency,dependent attenuation(FDA) of normal liver:0.55+0.05dB/cm/MHZ
2; FDA of normal spleen:0.37+0.06dB/cm/MHz
3; FDA of fatty liver:0.81+0.17dB/cm/MHz
4; FDA of liver cirrhosis:0.63+0.13dB/cm/MHz
5; FDA of chronic hepatitis:0.64+0.12dB/cm/MHz
6; FDA of hemangioma of liver:0.35+0.10dB/cm/MHz
7; FDA of cellular carcinoma:0.45+0.16dB/cm/MHz
8; FDA of metastatic liver carcinoma:0.43+0.15dB/cm/MHz
9; FDA of metastatic liver carcinoma from lung:0.38+0.12dB/cm/MHz
10; FDA of metastation liver carcinoma from colon:0.50+0.13dB/cm/MHz
11; FDA of normal thyroid gland:1.279+0.224dB/cm/MHz
12; FDA of normal breast:1.27+0.311dB/cm/MHz
13; FDA of chronic thyroiditis:0.824+0.325dB/cm/MHz
14; FDA of hyperthyroidism:0.729+0.319dB/cm/MHz
15; FDA of adenomatousgoiter:1.002+0.464dB/cm/MHz
16; FDA of adenoma:0.438+0.114dB/cm/MHz
17; FDA of thyroid papillary carcinoma:0.408+0.187dB/cm/MHz
18; FDA of breast carcinoma:1.513+0.452dB/cm/MHz
19; FDA of fibroadenoma:1.218+0.536dB/cm/MHz
20; FDA of gastrocunemius muscle:at rest0.42+0.13,at contraction0.86+0.32,and at strech0.30+0.14dB/cm/MHz
21; FDA of cerebrum:0.37+0.06dB/cm/MHz,cerebellum:0.52+0.14, thalamus:0.50+0.11dB/cm/MHz
|
